Weber Litchia L, Dunbar Nancy M, Meehan Kenneth R, Szczepiorkowski Zbigniew M, Lansigan Frederick
Department of Medicine, Dartmouth-Hitchcock Medical Center.
Department of Pathology and Medicine, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center.
J Clin Apher. 2015 Dec;30(6):359-63. doi: 10.1002/jca.21382. Epub 2015 Feb 17.
Extracorporeal photopheresis (ECP) is currently standard therapy for cutaneous T-cell lymphoma (CTCL) and Graft-versus-host disease (GVHD). Of the many challenges associated with outpatient ECP treatments, commuter travel to capable facilities can fragment and compromise the patient care. In 2008, our hospital implemented an ECP program providing patients to a treatment center over 120 minutes away. This study was undertaken to describe our experience with the establishment of a regional ECP program.
A retrospective review using a standardized template was performed of patients treated from May 2008 to 2012. The response to treatment was analyzed after a minimum of eight procedures. A partial response to treatment in individuals with CTCL, was more than 50% skin improvement, and GVHD, a reduction in steroid dose by 50%, liver function test improvement or documented improvement in skin findings.
Of the 34 patients treated, 11 were for CTCL and 23 for GVHD. 95.8% of the 1,071 planned procedures were successfully. The average procedure time was 186 min for the UVAR-XTSTM and 93 min for the CELLEXTM. Patients travelled a median of 65.7 miles (range 4-133 miles). The median duration of therapy was 6 months (range 2-23) for CTCL and 5 months (range 1-27) for GVHD. A clinical benefit was observed in 7 of 11 (63.6%) patients with CTCL and in 15 of 23 (65.2%) with GVHD.
Our regional ECP program was a viable option in improving access to care for patients requiring treatment for CTCL and chronic GVHD.
体外光化学疗法(ECP)目前是皮肤T细胞淋巴瘤(CTCL)和移植物抗宿主病(GVHD)的标准疗法。在门诊ECP治疗相关的诸多挑战中,前往有能力开展治疗的机构通勤可能会使患者护理碎片化并受到影响。2008年,我院实施了一项ECP项目,为距离超过120分钟路程的治疗中心的患者提供治疗。本研究旨在描述我们建立区域ECP项目的经验。
使用标准化模板对2008年5月至2012年接受治疗的患者进行回顾性分析。在至少进行8次治疗后分析治疗反应。CTCL患者治疗出现部分反应为皮肤改善超过50%,GVHD患者为类固醇剂量降低50%、肝功能检查改善或皮肤表现有记录的改善。
在接受治疗的34例患者中,11例为CTCL,23例为GVHD。1071次计划治疗中有95.8%成功完成。UVAR-XTSTM的平均治疗时间为186分钟,CELLEXTM为93分钟。患者的中位行程为65.7英里(范围4 - 133英里)。CTCL患者的中位治疗持续时间为6个月(范围2 - 23个月),GVHD患者为5个月(范围1 - 27个月)。11例CTCL患者中有7例(63.6%)、23例GVHD患者中有15例(65.2%)观察到临床获益。
我们的区域ECP项目是改善CTCL和慢性GVHD患者治疗可及性的可行选择。